| HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. | |
| | |
MedLine Citation:
|
PMID: 17898099 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].). |
| | |
Authors:
|
Philip Barter; Antonio M Gotto; John C LaRosa; Jaman Maroni; Michael Szarek; Scott M Grundy; John J P Kastelein; Vera Bittner; Jean-Charles Fruchart; |
Related Documents
:
|
21530799 - All-natural nitrite and nitrate containing dietary supplement promotes nitric oxide pro... 6612689 - The effect of variable fat diets and cholesterol-lowering drugs on antithrombin iii lev... 2975629 - Metabolic effects of combined cyproterone acetate and percutaneous 17 beta oestradiol a... 10428319 - Hormone replacement therapy and lipid-lipoprotein concentrations. 16295049 - Glycemic optimization may reduce lipid peroxidation independent of weight and blood lip... 9647339 - Long-term intraindividual variability of serum lipids in patients with type i and type ... 8385479 - Favorable long-term effect of a low-fat/high-fiber diet on human blood coagulation and ... 15853509 - Cholesterol homeostasis and the pathophysiology of alzheimer's disease. 10788729 - Do changes in physical activity lead to dietary changes in middle and old age? |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The New England journal of medicine Volume: 357 ISSN: 1533-4406 ISO Abbreviation: N. Engl. J. Med. Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-09-27 Completed Date: 2007-10-02 Revised Date: 2009-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1301-10 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright 2007 Massachusetts Medical Society. |
Affiliation:
|
Heart Research Institute, Sydney, Australia. barterp@hri.org.au |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00327691 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anticholesteremic Agents / therapeutic use Apolipoproteins / blood Cardiovascular Diseases / epidemiology* Cholesterol, HDL / blood* Cholesterol, LDL / blood* Coronary Disease / blood*, drug therapy Double-Blind Method Female Heptanoic Acids / administration & dosage, therapeutic use* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage, therapeutic use* Hypercholesterolemia / drug therapy Male Middle Aged Multivariate Analysis Pyrroles / administration & dosage, therapeutic use* Risk |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Apolipoproteins; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin |
| Comments/Corrections | |
Comment In:
|
Curr Atheroscler Rep. 2008 Aug;10(4):281
[PMID:
18606093
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antibodies against MICA antigens and kidney-transplant rejection.
Next Document: Evidence of MEN-2 in the original description of classic pheochromocytoma.